Last update 08 May 2025

AT-I9 (Ucello Therapeutics)

Overview

Basic Info

Drug Type
Universal CAR-T
Synonyms
Target
CD19
Action
inhibitors
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication-
Inactive Indication
B-Cell LymphomaCD19 Positive LymphomaCD19-positive B-cell acute lymphoblastic leukemia+ [3]
Originator Organization
Chengdu Ucello Therapeutics Co., LtdChengdu Ucello Therapeutics Co., Ltd
Active Organization-
Inactive Organization
Chengdu Ucello Therapeutics Co., LtdChengdu Ucello Therapeutics Co., Ltd
License Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with AT-I9 (Ucello Therapeutics)
NCT04796688
/ Unknown statusPhase 1IIT
Safety and Efficacy of Universal Chimeric Antigen Receptor-modified AT19 Cells in Patients With CD19+ Relapsed/Refractory Hematological Malignancies: a Single-center, Open-label, Single-arm Clinical Study
100 Clinical Results associated with AT-I9 (Ucello Therapeutics)
Login to view more data
100 Translational Medicine associated with AT-I9 (Ucello Therapeutics)
Login to view more data
100 Patents (Medical) associated with AT-I9 (Ucello Therapeutics)
Login to view more data
100 Deals associated with AT-I9 (Ucello Therapeutics)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-Cell LymphomaPhase 1
China
Chengdu Ucello Therapeutics Co., LtdChengdu Ucello Therapeutics Co., Ltd
10 Mar 2021
CD19 Positive LymphomaPhase 1
China
Chengdu Ucello Therapeutics Co., LtdChengdu Ucello Therapeutics Co., Ltd
10 Mar 2021
CD19-positive B-cell acute lymphoblastic leukemiaPhase 1
China
Chengdu Ucello Therapeutics Co., LtdChengdu Ucello Therapeutics Co., Ltd
10 Mar 2021
Chronic Lymphocytic LeukemiaPhase 1
China
Chengdu Ucello Therapeutics Co., LtdChengdu Ucello Therapeutics Co., Ltd
10 Mar 2021
Pre B-cell acute lymphoblastic leukemiaPhase 1
China
Chengdu Ucello Therapeutics Co., LtdChengdu Ucello Therapeutics Co., Ltd
10 Mar 2021
Recurrent Hematologic MalignancyPhase 1
China
Chengdu Ucello Therapeutics Co., LtdChengdu Ucello Therapeutics Co., Ltd
10 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free